Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ZAAPS Program results for 2015: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 32 countries

29 Jun 2017

Abstract excerpt

OBJECTIVES: To report the linezolid in vitro activity obtained during the 2015 ZAAPS Program. METHODS: In total, 7587 organisms causing documented infections were consecutively collected in 65 centres in 32 ex-USA countries. Broth microdilution susceptibility testing was performed. Isolates displaying linezolid MIC results of ≥ 4 mg/L were molecularly characterized. RESULTS: Linezolid inhibited >99.9% of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimicrobial Resistance in Staphylococcus
Share to Bacterial biofilms and quorum sensing
Share to Bacterial Identification and Susceptibility Testing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28961701
DOI: 10.1093/jac/dkx251

Provenance

PubMed metadata and Literature Corpus relationships.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ZAAPS Program results for 2015: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 32 countriesPMID 28961701Read ↗

ZAAPS programme results for 2016: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 42 countries.Semantic proximity Read ↗

Five-Year Summary of In Vitro Activity and Resistance Mechanisms of Linezolid against Clinically Important Gram-Positive Cocci in the United States from the LEADER Surveillance Program (2011 to 2015)Semantic proximity Read ↗

Zyvox(R) Annual Appraisal of Potency and Spectrum (ZAAPS) Program: report of linezolid activity over 9 years (2004-12)Semantic proximity Read ↗

Linezolid update: stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms.Semantic proximity Read ↗

Surveillance for linezolid resistance via the Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) programme (2014): evolving resistance mechanisms with stable susceptibility rates.Semantic proximity Read ↗

ZAAPS International Surveillance Program (2007) for linezolid resistance: results from 5591 Gram-positive clinical isolates in 23 countriesSemantic proximity Read ↗

Linezolid Surveillance Results for the United States (LEADER Surveillance Program 2014).Semantic proximity Read ↗

LEADER Program results for 2009: an activity and spectrum analysis of linezolid using 6,414 clinical isolates from 56 medical centers in the United States.Semantic proximity Read ↗

Zyvox® Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countriesSemantic proximity Read ↗

Linezolid in the Focus of Antimicrobial Resistance of Enterococcus Species: A Global Overview of Genomic StudiesSemantic proximity Read ↗

The emerging problem of linezolid-resistant enterococci.Semantic proximity Read ↗

Molecular Characteristics and Antimicrobial Resistance of Linezolid-Resistant Staphylococcus aureus in Osteoarticular Infections: A 11-Year Study From a Hospital in Xi’anSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.